A novel adipokine GM2AP impairs insulin signaling

Biochemical and Biophysical Research Communications

Volumn 402, Issue 3, 2010, Pages 571-576

  Higashi, Kiyoshi ^a   Mikami, Toshiyuki ^b   Yamada, Toru ^b   Kawashima, Hitoshi ^b   Kimura, Toru ^b   Kaneko, Hideo ^a  

^a SUMITOMO CHEMICAL CO LTD   (Japan)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Adipokine; Caveolin; GM2AP; Insulin; NGF

Indexed keywords

ANTIBODY; CAVEOLIN 1; GANGLIOSIDE GM2 ACTIVATOR PROTEIN; GLUCOSE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR BETA; MESSENGER RNA; NERVE GROWTH FACTOR; UNCLASSIFIED DRUG;

ADIPOGENESIS; ADIPOSE TISSUE; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN; CELL STRAIN 3T3; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GLUCOSE TRANSPORT; HUMAN; LEAN BODY WEIGHT; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ADIPOKINES; ANIMALS; CELLS, CULTURED; G(M2) ACTIVATOR PROTEIN; HUMANS; INSULIN; MICE; OBESITY; PROTEOMICS; RATS;

MUS; RATTUS;

EID: 78549254475     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.10.110     Document Type: Article

References (29)

1. Ode K.L., Frohnet B.I., Nathan B.M. Identification and treatment of metabolic complications in pediatric obesity. Rev. Endocr. Metab. Disord. 2009, 10:167-188.
2. Han S.H., Sakuma I., Shin E.K., Koh K.K. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog. Cardiovasc. Dis. 2009, 52:126-140.
3. Cameron A.J., Dunstan D.W., Owen N., Zimmet P.Z., Barr E.L., Tonkin A.M., Magliano D.J., Murray S.G., Welborn T.A., Shaw J.E. Health and mortality consequences of abdominal obesity: evidence from the AusDiab study. Med. J. Aust. 2009, 191:202-208.
4. Rabe K., Lehrke M., Parhofer K.G., Broedi U.C. Adipokines and insulin resistance. Mol. Med. 2008, 14:741-751.
5. Vazquez M.J., Gonzalez C.R., Varela L., Lage R., Tovar S., Sangiano-Alvarellos S., Williams L.M., Vidal-Puig A., Nogueiras R., Lopez M., Diequez C. Central resistin regulates hypothalamic and peripheral lipid metabolism in a nutritional-dependent fashion. Endocrinology 2008, 149:4534-4543.
6. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., Patel H.R., Ahima R.S., Lazar M.A. The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
7. Giese K., Fantl W.J., Vitt C., Stephans J.C., Cousens L., Wachowicz M., Williams L.T. Reduction of food intake and weight gain by the ob protein requires a specific secondary structure and is reversible. Mol. Med. 1996, 2:50-58.
8. Rigat B., Yeger H., Shehnaz D., Mahuran D. GM2 activator protein inhibits platelet activating factor signaling in rats. Biochem. Biophys. Res. Commun. 2009, 385:576-580.
9. Wright C.S., Li S.C., Rastinejad F. Crystal structure of human GM2-activator protein with a novel beta-cup topology. J. Mol. Biol. 2000, 304:411-422.
10. Mathias J.D., Ran Y., Carter J.D., Fanucci G.E. Interactions of the GM2 activator protein with phosphatidylcholine bilayers: a site-directed spin-labeling power saturation study. Biophys. J. 2009, 97:1436-1444.
11. Ran Y., Fanucci G.E. Ligand extraction properties of the GM2 activator protein and its interactions with lipid vesicles. Biophys. J. 2009, 97:257-266.
12. Kolter T., Sandhoff K. Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Ann. Rev. Cell. Dev. Biol. 2005, 21:81-103.
13. Shimada Y., Li Y.T., Li S.C. Effect of GM2 activator protein on the enzymatic hydrolysis of phospholipids and sphingomyelin. J. Lipid Res. 2003, 44:342-348.
14. Christine S.W., Li Z.M., Sangderk L., Fraydoon R. Crystal structure analysis of phosphatidylcholine-GM2-activator product complexes: evidence for hydrolase activity. Biochemistry 2005, 44:13510-13521.
15. Yanai H., Yoshida H., Tomono Y., Tada N., Chiba H. The possible contribution of a general glycosphingolipid transporter, GM2 activator protein, to therosclerosis. J. Atheroscler. Thromb. 2006, 13:281-285.
16. Higashi K., Inagaki Y., Fujimori F., Nakao A., Kaneko H., Nakatsuka I. Interferon-γ interferes with transforming growth factor-β signaling through direct interaction of YB-1 with Smad3. J. Biol. Chem. 2003, 278:43470-43479.
17. Wendeler M., Lemm T., Weisgerber J., Hoernschemeyer J., Bartelsen O., Schepers U., Sandhoff K. Expression of recombinant human GM2-activator protein in insect cells: purification and characterization by mass spectrometry. Protein Expr. Purif. 2003, 27:259-266.
18. Inagaki Y., Higashi K., Kushida M., Hong Y.Y., Nakao S., Higashiyama R., Moro T., Itoh J., Mikami T., Kimura T., Shiota G., Kuwabara I., Okazaki I. Hepatocyte growth factor suppresses profibrotic signal transduction via nuclear export of Smad3 with galectin-7. Gastroenterology 2008, 134:1180-1190.
19. Yamamoto N., Sato T., Kawasaki K., Murosaki S., Yamamoto Y. A nonradioisotope, enzymatic assay for 2-deoxyglucose uptake in L6 skeletal muscle cells cultured in a 96-well microplate. Anal. Biochem. 2006, 351:139-145.
20. Beccari T., Palmerini C.A., Servillo G., Della-Fazia M.A., Viola-Magni M.P., Orlacchio A. GM2 activator protein expression in mouse tissues. Biochem. Biophys. Res. Commun. 1994, 204:741-745.
21. Beccari T., Balducci C., Aisa M.C., Della-Fazia M.A., Servillo G., Orlacchio A. Promoter characterization and expression of the gene coding for the human GM2 activator protein. Biosci. Rep. 2001, 21:55-62.
22. Chang L., Chiang S.H., Saltiel A.R. Insulin signaling and the regulation of glucose transport. Mol. Med. 2004, 10:65-71.
23. Kabayama K., Sato T., Saito K., Loberto N., Prinetti A., Sonnino S., Kinjo M., Igarashi Y., Inokuchi J. Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Proc. Natl. Acad. Sci. USA 2007, 104:13678-13683.
24. Pitto M., Mutoh T., Kuriyama M., Ferraretto A., Palestini P., Masserini M. Influence of endogenous GM1 ganglioside on TrkB activity, in cultured neurons. FEBS Lett. 1998, 439:93-96.
25. Mutoh T., Tokuda A., Miyadai T., Hamaguchi M., Fujiki N. Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc. Natl. Acad. Sci. USA 1995, 92:5087-5091.
26. Zhang J., Wu Y.J., Zhang Y., LeRoith D., Bernlohr D.A., Chen X. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol. Endocrinol. 2008, 22:1416-1426.
27. Rabe K., Lehrke M., Parhofer K.G., Broedl U.C. Adipokines and insulin resistance. Mol. Med. 2008, 14:741-751.
28. Hakomori S. Glycosynapses: microdomains controlling carbohydrate-dependent cell adhesion and signaling. An. Acad. Bras. Cienc. 2004, 76:553-572.
29. Teruel T., Hernandez R., Lorenzo M. Ceramide mediates insulin resistance by tumor necrosis factor-α in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes 2001, 50:2563-2571.